BioXcel Therapeutics
BTAI
35 hedge funds and large institutions have $1.19M invested in BioXcel Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
275% more call options, than puts
Call options by funds: $15K | Put options by funds: $4K
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
55% more capital invested
Capital invested by funds: $770K → $1.19M (+$423K)
13% more funds holding
Funds holding: 31 → 35 (+4)
1.31% less ownership
Funds ownership: 11.52% → 10.21% (-1.3%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$399K |
| 2 |
OFA
Oaktree Fund Advisors
Los Angles,
California
|
+$71K |
| 3 |
Jones Financial Companies
Des Peres,
Missouri
|
+$43K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$40.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$38.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$102K |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$91.8K |
| 3 |
Goldman Sachs
New York
|
-$50.3K |
| 4 |
VF
Virtu Financial
New York
|
-$22K |
| 5 |
BlackRock
New York
|
-$9.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $81 | -$118 | -71 | -61% |
|
27
BNP Paribas Financial Markets
Paris,
France
| $80 | – | – | – |
|
|
NA
28
NewEdge Advisors
New Orleans,
Louisiana
| $57 | – | – | – |
|
29
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $38 | – | – | – |
|
30
Barclays
London,
United Kingdom
| $14 | -$3.15K | -1,902 | -100% |
|
31
National Bank of Canada
Montreal,
Quebec, Canada
| $11 | -$35 | -21 | -78% |
|
|
DB
32
Danske Bank
Copenhagen K,
Denmark
| $5 | – | – | – |
|
|
FDCDDQ
33
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2 | -$3 | -2 | -67% |
|
34
US Bancorp
Minneapolis,
Minnesota
| $2 | – | – | – |
|
|
MYIA
35
Mount Yale Investment Advisors
Denver,
Colorado
| $2 | +$2 | +1 | New |
|
|
36
Goldman Sachs
New York
| – | -$50.3K | -24,794 | Closed |
|
|
VF
37
Virtu Financial
New York
| – | -$22K | -10,666 | Closed |
|
38
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$481 | -237 | Closed |
|
39
Fidelity Investments
Boston,
Massachusetts
| – | -$22 | -11 | Closed |
|
|
FFA
40
Farther Finance Advisors
San Francisco,
California
| – | -$10 | -5 | Closed |
|
BTAI Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2025, worth a combined $1.19M — up 55% from $770K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BTAI positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Oaktree Capital Management, opening a new position worth an estimated $399K. The largest seller was UBS Group, cutting an estimated $102K.
- 35 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2025, up from 31 in Q1 2025.
- Funds reported $1.19M of BioXcel Therapeutics stock for Q2 2025, up 55% quarter-over-quarter.
- 9 funds opened new BioXcel Therapeutics positions in Q2 2025 and 5 closed out, a net change of +4 holders.
- The largest BioXcel Therapeutics buyer in Q2 2025 was Oaktree Capital Management, an estimated $399K added.
- The largest BioXcel Therapeutics seller in Q2 2025 was UBS Group, an estimated $102K sold.
Based on aggregated 13F filings for Q2 2025.